Alumis Inc.
ALMS- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001847367
In the last 90 days, Alumis Inc. insiders filed 1 open-market purchase and 7 sales; 198 institutions reported holding it in 13F filings for Q2 2026, worth $3.32B in total; no superinvestor holds it.
Key figures
- Market capNo recent share count in SEC filings
- –
- Insider buysLast 90 days, $10.7M in total
- 1
- Insider sellsLast 90 days, $1.04M in total
- 7
- 13F holdersQ2 2026, +4 vs. previous quarter
- 198
- 13F valueReported value at the end of Q2 2026
- $3.32B
- Superinvestors holdingAt the end of Q2 2026
- 0
Price chart
Financials
See financial statementsFrom SEC filings, in USD.
- Revenue, FY2025
- $24.1M
- No comparable prior period
- Net income, FY2025
- -$243.3M
- No comparable prior period
- Free cash flow, FY2025
- -$370.2M
- No comparable prior period
- Revenue, Q2 FY2026
- $1.66M
- −37.7% year over year
Revenue flow, FY2025
Green is profit; orange is costs, expenses and taxes. Percentages are shares of revenue.
Net loss for FY2025: $243.3M (1011.7% of revenue).
Short interest
See short dataFrom FINRA, settlement date Oct 30, 2026.
- Short interest
- 11.0M
- Shares sold short
- Change
- −47.8K
- −0.4% vs. previous
- Days to cover
- 5.78
- At average daily volume
Superinvestors holding ALMS, Q2 2026
Go to the superinvestors tabNo superinvestor reported holding ALMS at the end of Q2 2026.
Latest insider trades
See all insider tradesOpen-market purchases and sales by Alumis Inc. insiders from Form 4, newest first.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Nov 4, 2026 (view filing)4:46 PM ET | Nov 2 | 2 days | Schroer John R.Chief Financial Officer | SSale | −794 | $6.52 | −$5.18K | −3.2%23.9K after | |
| Nov 4, 2026 (view filing)4:41 PM ET | Nov 2 | 2 days | Pangali SanamChief Legal Officer | SSale | −332 | $6.52 | −$2.16K | −3.4%9.41K after | |
| Nov 4, 2026 (view filing)4:37 PM ET | Nov 2 | 2 days | Hardiman Roy C.Chief Business & Strategy Ofcr | SSale | −652 | $6.52 | −$4.25K | −0.3%207.1K after | |
| Nov 4, 2026 (view filing)4:35 PM ET | Nov 2 | 2 days | Goldstein David MChief Scientific Officer | SSale | −629 | $6.52 | −$4.10K | −2.0%30.3K after | |
| Nov 4, 2026 (view filing)4:22 PM ET | Nov 2 | 2 days | Drappa JornChief Medical Officer | SSale | −593 | $6.52 | −$3.87K | −1.0%56.3K after | |
| Nov 4, 2026 (view filing)4:19 PM ET | Nov 2 | 2 days | Bradley Mark ChristopherChief Development Officer | SSale | −623 | $6.52 | −$4.06K | −1.3%47.9K after | |
| Sep 9, 2026 (view filing)9:39 PM ET | Sep 4-8 | 5 days | Akkaraju SrinivasDirector | PPurchase | +986.7K | $10.87 | +$10.7M | +75.2%2.30M after | 4 lots |
| Sep 9, 2026 (view filing)9:39 PM ET | Sep 8 | 1 day | Akkaraju SrinivasDirector | SSale | −96.1K | $10.55 | −$1.01M | −4.5%2.03M after | 2 lots |
| Aug 5, 2026 (view filing)6:50 PM ET | Aug 3 | 2 days | Schroer John R.Chief Financial Officer | SSale | −3.28K | $26.37 | −$86.5K | −11.7%24.7K after | |
| Aug 5, 2026 (view filing)6:46 PM ET | Aug 3 | 2 days | Pangali SanamChief Legal Officer | SSale | −1.36K | $26.37 | −$36.0K | −12.3%9.75K after |
Top 10 13F holders, Q2 2026
See all 198 holdersThe largest institutional positions in Alumis Inc. at the end of Q2 2026; share changes are against Q1 2026.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| AyurMaya Capital Management Company, LP | 15,139,707 | $426.0M | 100.00% | 00.0% | Unchanged |
| BlackRock, Inc. | 8,218,151 | $231.3M | 0.00% | +1,047,283+14.6% | Added |
| FMR LLC | 6,769,170 | $190.5M | 0.01% | +5,795,388+595.1% | Added |
| Deep Track Capital, LP | 6,348,558 | $178.6M | 2.63% | −424,037−6.3% | Reduced |
| Samsara BioCapital, LLC | 6,345,219 | $178.6M | 14.67% | 00.0% | Unchanged |
| Foresite Capital Management V, LLC | 5,896,995 | $165.9M | 45.81% | 00.0% | Unchanged |
| Price T Rowe Associates Inc | 5,199,838 | $146.3M | 0.01% | +1,913,085+58.2% | Added |
| venBio Partners LLC | 4,528,408 | $127.4M | 24.53% | 00.0% | Unchanged |
| Foresite Capital Management VI LLC | 4,247,670 | $119.5M | 18.60% | 00.0% | Unchanged |
| Vanguard Capital Management LLC | 4,215,703 | $118.6M | 0.00% | +183,437+4.5% | Added |
Holders of 5% or more of ALMS
See all 6 holders and filingsHolders whose latest Schedule 13D or 13G filing reports 5% or more of Alumis Inc..
| Holder | Latest form | Stake | Change | First filed | Latest filing | Filing |
|---|---|---|---|---|---|---|
| Foresite Capital Fund VI LP | 13D | 14.50%9.18M shares | New | Aug 17, 20261 filing | Aug 17, 2026 | SEC |
| Foresite Capital Fund VI LP | 13D/A | 12.70%15.7M shares | −1.40 ppfrom 14.10% | Jul 5, 20245 filings | Apr 3, 2026 | SEC |
| AyurMaya Capital Management Company, LP | 13D/A | 12.30%15.1M shares | −3.50 ppfrom 15.80% | Jul 3, 20244 filings | Jul 2, 2026 | SEC |
| Deep Track Capital, LP | 13G | 5.98%7.36M shares | New | Apr 7, 20261 filing | Apr 7, 2026 | SEC |
| BlackRock, Inc. | 13G | 5.70%7.07M shares | New | Jul 27, 20261 filing | Jul 27, 2026 | SEC |